• By Donald Zuhn —

    USPTO Seal On March 31, the U.S. Patent and Trademark Office announced that it was implementing a new e-Petitions system and that eight different petitions would initially be made available through the system.  The e-Petitions system automates the petitions process so that applicants can input the requisite data into a secure web interface and receive a decision automatically, thereby eliminating the time that would ordinarily be spent having a petition docketed, decided, and uploaded into Public PAIR (Patent Application Information Retrieval).  USPTO Director David Kappos stated that the e-Petitions system was a response to complaints from stakeholders that "it takes too long to get a decision from the Petitions Office."

    The eight petitions that are being made available through the system include:

    1. Withdrawal of attorney

    2. Withdraw from issue after payment of the issue fee

    3. Withdraw from issue after payment of the issue fee under 37 C.F.R. § 1.313(c)

    4. Withdraw from issue after payment of the issue fee under 37 C.F.R. § 1.313(c)(1) or (2) when patent number is assigned

    5. Withdraw from issue under 37 C.F.R. § 1.313(c)(3)

    6. Petition to accept late payment of issue fee — unintentional standard under 37 C.F.R. §§ 1.155(c) or 1.316

    7. Petitions for revival under 37 C.F.R. § 1.137(f)

    8. Petitions to revive an abandoned application under 37 C.F.R. § 1.137(b) for continuity purposes only

    The Office noted that the eight petitions above account for approximately one-third of the work of the Petitions Office, and join two other types of patent petitions that are already decided electronically, i.e., petitions to make special on the basis of age and petitions to accept unintentionally delayed payment of the maintenance fee.  According to a FAQs webpage on web-based e-Petitions, the Office plans to monitor the response to the eight initial petitions before converting other petitions to the web-based e-Petition format.

  • By Sherri Oslick —

    Gavel About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases.

    Eli Lilly and Company v. Accord Healthcare, Inc.
    1:11-cv-00261; filed April 4, 2011 in the District Court of North Carolina

    Infringement of U.S. Patent No. 5,919,485 ("Oral 2-Methyl-thieno-benzodiazepine Formulation," issued July 6, 1999) following a Paragraph IV certification as part of Accord's filing of an ANDA to manufacture a generic version of Lilly's Zyprexa® (olanzapine, used to treat schizophrenia and acute manic episodes associated with bipolar mania).  View the complaint here.


    Novartis AG v. Kappos

    1:11-cv-00659; filed April 1, 2011 in the District Court of the District of Columbia

    Review and correction of the patent term adjustment calculation made by the U.S. Patent and Trademark Office for U.S. Patent No. 7,807,155 ("IL-17 Antagonistic Antibodies," issued October 5, 2010).  View the complaint here.


    Elan Corp. PLC et al. v. Mylan Pharmaceuticals Inc.

    1:11-cv-00281; filed April 1, 2011 in the District Court of Delaware

    • Plaintiffs:  Elan Corp. PLC; Elan Pharma International Ltd.
    • Defendant:  Mylan Pharmaceuticals Inc.

    Infringement of U.S. Patent Nos. 6,228,398 ("Multiparticulate Modified Release Composition," issued May 8, 2001) and 6,730,325 (same title, issued May 4, 2004), licensed to Novartis, following a Paragraph IV certification as part of Mylan's filing of an ANDA to manufacture a generic version of Novartis' Focalin® XR (extended release dexmethylphenidate hydrochloride, used to treat attention deficit hyperactivity disorder).  View the complaint here.


    Takeda Pharmaceutical Co., Ltd. et al. v. Dr. Reddy's Laboratories, Ltd. et al.

    1:11-cv-02253; filed April 1, 2011 in the Southern District of New York

    • Plaintiffs:  Takeda Pharmaceutical Co., Ltd.; Takeda Pharmaceuticals North America, Inc.; Takeda Pharmaceuticals LLC; Takeda Pharmaceuticals America, Inc.
    • Defendants:  Dr. Reddy's Laboratories, Ltd.; Dr. Reddy's Laboratories, Inc.

    Infringement of U.S. Patent Nos. 6,664,276 ("Benzimidazole Compound Crystal,", issued December 16, 2003) and 7,790,755 ("Controlled Release Preparation," issued September 7, 2010) following a Paragraph IV certification as part of Dr. Reddy's filing of an ANDA to manufacture a generic version of Takeda's Dexilant® (dexlansoprazole, used for the treatment of all grades of erosive esophagitis, maintaining healing of esophagitis, and treating heartburn associated with symptomatic non-erosive gastroesophageal reflux disease).  View the complaint here.


    Life Technologies Corp. v. Pacific Biosciences of California, Inc
    .
    5:11-cv-01582; filed March 31, 2011 in the Northern District of California

    Review of the decision of the Board of Patent Appeals and Interferences awarding priority of invention to PacBio in the interference between U.S. Patent No. 7,329,492 ("Methods for Real-Time Single Molecule Sequence Determination," issued February 12, 2008), assigned to Life Technologies and U.S. Patent Application No. 11/459,182 ("A System and Method for Nucleic Acid Sequencing by Polymerase Synthesis," filed July 21, 2006), assigned to PacBio.  View the complaint here.


    Lupin Atlantis Holdings S.A. v. Ranbaxy Laboratories Ltd. et al.

    2:11-cv-02295; filed March 31, 2011 in the Eastern District of Pennsylvania

    • Plaintiff:  Lupin Atlantis Holdings S.A.
    • Defendants:  Ranbaxy Laboratories Ltd.; Ranbaxy Pharmaceuticals Inc.; Ranbaxy, Inc.; Ethypharm S.A.

    Infringement of U.S. Patent No. 7,863,331 ("Pharmaceutical Composition Containing Fenofibrate and Method for the Preparation Thereof," issued January 4, 2011) following a Paragraph IV certification as part of Ranbaxy's filing of an ANDA to manufacture a generic version of Lupin's Antara® (fenofibrate, used to treat hypercholesterolemia and hypertriglyceridemia).  View the complaint here.

  • By Donald Zuhn —

    USPTO Seal Last week, the U.S. Patent and Trademark Office announced that it would begin accepting requests for prioritized examination of patent applications on May 4, 2011.  The program was initially announced as part of the Enhanced Examination Timing Control Initiative (or Three Track program) last June (see "USPTO Publishes Notice Regarding Enhanced Examination Timing Control Initiative").

    In February, the Office indicated that the first phase of the Three Track proposal (i.e., Track 1 examination, which would provide prioritized examination of an application within 12 months of its filing date) would carry a hefty additional fee of $4,000 (see "USPTO Provides More Details Regarding 'Three Track' Examination Proposal").  The Office also indicated that Track 1 applications would be limited to four independent and thirty total claims and would have to be filed electronically via the EFS-Web.  Finally, the Office noted that in view of the support for Track 1, it would be proceeding with "immediate implementation" of the prioritized examination track.

    In last week's announcement, the Office noted that requests for prioritized examination would be limited to a maximum of 10,000 applications from May 4 to September 30, 2011 (when the Office's fiscal year 2011 ends).  The Office also published a notice in the Federal Register (76 Fed. Reg. 18399) providing changes for implementing the Track 1 program.  In the notice, the Office states that "[t]he aggregate goal for processing applications under prioritized examination is to provide a final disposition within twelve months of prioritized status being granted."

    In addition to the $4,000 fee for requesting priority examination (for which small entities will not at present receive a 50% discount), applicants will still have to pay standard filing fees (including excess claims and application size fees) and processing and publication fees.  As the notice explains, large entity applicants can expect to pay a minimum of $5,520 for priority examination ($330 for the basic filing fee, $540 for the search fee, $220 for the examination fee, $4,000 for the prioritized examination fee, $130 for the processing fee, and $300 for the publication fee).  The notice also states that if the America Invents Act is enacted, giving the Office more fee-setting authority with respect to priority examination, the priority examination fee will be increased to $4,800 for large entities and decreased to $2,400 for small entities.

    While the Office will accord prioritized examination applications special status and place them on the examiner's special docket, the following actions taken by the applicant will terminate prioritized examination:

    • Filing a request for continued examination (RCE);
    • Filing a petition for an extension of time to file a reply;
    • Filing a request for a suspension of action; or
    • Filing an amendment that results in more than four independent claims, more than thirty total claims, or a multiple dependent claim.

    To participate in the Track I program, applicants have to fulfill the following requirements:

    • File a new original utility or plant nonprovisional application under 35 U.S.C. § 111(a) on or after May 4, 2011 (the procedure does not apply to international, design, reissue, or provisional applications, or reexamination proceedings, but can be used for continuing applications);
    • File an application that is complete under 37 C.F.R. § 1.51(b), including the oath or declaration, and payment of the filing, search, and examination fees, any applicable excess claims fee, and any applicable application size fee at the time of filing;
    • File the application via the Office's electronic filing system (EFS-Web);
    • The application cannot contain more than four independent claims and thirty total claims or any multiple dependent claims;
    • Request prioritized examination (preferably by using Form PTO/SB/424); and
    • Pay the required fees for requesting prioritized examination at the time of filing (i.e., the prioritized examination fee set forth in 37 C.F.R. § 1.17(c), the processing fee set forth in 37 C.F.R. § 1.17(i), and the publication fee set forth in 37 C.F.R. § 1.18(d)).

    The remainder of the Federal Register notice provides responses to 24 comments submitted on the Track 1 proposal, and amendments to the Rules of Practice for implementing the program.

    The Office indicated last week that Track 3, which would allow an applicant to request a delay of up to 30 months prior to docketing for examination, would likely be implemented by September 30, 2011.

  • By James DeGiulio —

    Fabrazyme Last year, following Genzyme's inability to supply patient needs for the enzyme replacement drug Fabrazyme, concerned Fabry patients petitioned the Department for Health and Human Services (HHS) to exercise the government's "march-in" rights under the Bayh-Dole Act and force Genzyme to license the patents covering the drug to other manufacturers who can produce the needed Fabrazyme quantities (see "Genzyme's Manufacturing Issues with Fabrazyme Prompt Patients to Petition HHS Secretary to Exercise Bayh-Dole 'March-in' Rights").  That petition was denied on December 1, 2010, and Fabry patients resorted to bringing a civil suit against the Food and Drug Administration for damages caused by the shortage (see "Fabry Patients Sue Genyzme for Damages Caused By Fabrazyme Rationing").  Genzyme has since reported additional manufacturing errors at its Massachusetts plant that will further delay U.S. Fabry patients access to the drug.  Fearful that Genzyme will continue to delay restoring production of Fabrazyme indefinitely, Fabry patients on April 5 once again asked for relief from the NIH by filing a petition for rehearing of their 2010 march-in request.

    Genzyme On March 23, Genzyme announced that due to vial contamination issues, it had changed the predicted date of restoration of Fabrazyme supply from early 2011 to late 2011.  Additionally, Genzyme announced that due to the loss, it would re-allocate drug away from American patients to overseas markets.  According to the petition for rehearing, this is the ninth consecutive time that Genzyme has pushed back the projected deadline.  The NIH kept the request for march-in open upon receiving information that "progress toward restoring the supply of Fabrazyme to meet patient demand was not proceeding as represented," and that it would revisit the petition upon receiving such information.  Fabry patients have requested rehearing because the latest information from Genzyme contradicts Genzyme's original representations to the NIH.  Genzyme's assurance to the NIH was that it expected to restore full access to patients in the first half of 2011, a deadline which the company appears to be unable to meet based on the latest manufacturing problems.  According to the petition for rehearing, the NIH must now presume, for the protection of Fabry patients, that Genzyme will de facto never be able to reliably supply Fabrazyme to meet patient needs.  Fabry patients ask that another manufacturer be provided with a license to the Fabrazyme patents in order to provide a second source of drug production should Genzyme fail once again.  The petition also cites a conflict of interest, asking for (among others) NIH director Francis Collins to recuse himself from reviewing their petition because they maintain he has a financial interest in at least nineteen federally-funded inventions, which creates "at least the appearance of a conflict of interest."

    For additional information regarding this topic, please see:

    • "Fabry Patients Sue Genyzme for Damages Caused By Fabrazyme Rationing," March 10, 2011
    • "U.S. Patients Petition FDA to Regulate Genzyme Export of Fabrazyme," January 25, 2011
    • "HHS Denies Request to Exercise Bayh-Dole 'March-in' Rights for Fabrazyme," December 9, 2010
    • "Genzyme's Manufacturing Issues with Fabrazyme Prompt Patients to Petition HHS Secretary to Exercise Bayh-Dole 'March-in' Rights," August 15, 2010

  • Calendar

    April 13-15, 2011 – Intellectual Property Counsels Committee (IPCC) Spring Conference & Meeting (Biotechnology Industry Organization) – Seattle, WA

    April 15, 2011 – 2nd Annual John Marshall Law School Review of Intellectual Property Law Symposium – Chicago, IL

    April 27, 2011 – 27th Annual Joint Patent Practice Seminar (Connecticut, New Jersey, New York, and Philadelphia Intellectual Property Law Associations) – New York, NY

    April 29, 2011 – Ethics in the Practice of Intellectual Property Law (John Marshall Law School Center for Intellectual Property Law) – Chicago, IL

    April 27-29, 2011 – Patent Strategies Summit*** (International Quality & Productivity Center) – Palo Alto, CA

    May 3-4, 2011 – Paragraph IV Disputes*** (American Conference Institute) – New York, NY

    May 18-19, 2011 – Forum on Freedom to Operate (C5) – Munich, Germany

    June 7-8, 2011 – Biosimilars*** (American Conference Institute) – New York, NY

    ***Patent Docs is a media partner of this conference or CLE

  • BrochureInternational Quality & Productivity Center (IQPC) will be holding its 7th Patent Strategies Summit from April 27-29, 2011 in Palo Alto, CA.  The summit will cover the following topics:

    • Changes in patent strategy brought about by the current economic downturn;
    • Best practices in global IP management;
    • Prospects for the future in light of new regulations and potentially adverse court decisions;
    • Trends in enforcement actions and litigation by NPEs;
    • Tips for licensing in and licensing out intellectual property; and
    • How and when to outsource your patents.

    In particular, the summit will offer presentations on:

    • Leveraging your patent portfolio to optimize your bottom line;
    • Managing patent litigation: Designing a business-wide intellectual property strategy;
    • How to successfully administer your patent strategy in any economic environment;
    • Examining patent outsourcing strategies and deciding what fits for your company;
    • Successfully integrating patents and business to extract innovation and financial gain;
    • False patent marking: Will your company be sued next?
    • Contemplating the current patent system: Is it better to dominate or to innovate?
    • Hot topics in patent law: Up-to-the-minute developments in the agencies;
    • Building and maintaining a global patent portfolio: Best practices to maximize profit and value;
    • Enhancing your licensing strategy to gain a competitive advantage and maximize revenue;
    • Evolving patent standards: How do recent developments in us patent law affect the patent filing strategy of your company?
    • Developing and implementing a patent strategy for start-up companies;
    • Panel discussion: Protecting your intellectual property when combining technologies from different industries; and
    • Patent protection in the pharmaceutical and biotech industry.

    Three additional pre-summit workshops will be offered on April 27, 2011.  Workshop A, entitled "The Patent Antitrust Dilemma: Making Full Use of Exclusivity Protections within the Bounds of Competition Law" will be offered from 9:00 am to 11:30 am, Workshop B, entitled "Patent Outsourcing: Reaping The Business Rewards While Managing The Legal Risks" will be offered from 11:45 am to 2:15 pm, and Workshop C, entitled "Green Technology: Exploring How Innovation and IP Will Help Meet Environmental Goals," will be offered from 2:30 pm to 5:00 pm.

    IQPC The agenda for the Patent Strategies Summit can be found here (Day 1), here (Day 2), and here (pre-summit workshops). A complete brochure for this conference, including an agenda, detailed descriptions of conference sessions, list of speakers, and registration form can be obtained here.

    Pricing for the conference and workshops can be found here.  Those interested in registering for the conference can do so here.

    Patent Docs is a preferred blog of the IQPC Patent Strategies Summit.

  • Munich, Germany C5 (UK) will be holding its 8th International Forum on Freedom to Operate on May 18-19, 2011 in Munich, Germany.  The conference will provide insights on FTO challenges and updates, including:

    • Executing successful and cost-effective search strategies;
    • Enforcing or defending patent claims in new markets;
    • Challenging validity to overcome blocking patents;
    • Capitalizing on the benefits of Supplementary Protection Certificates;
    • Obtaining market authorization to diversify your portfolio;
    • Maximizing the value of your portfolio through Paediatric Extension;
    • Acquiring data exclusivity to extend your patent protection in Europe;
    • Gaining FTO in emerging markets: A focus on China and India;
    • Implementing a strategy for managing FTO risks of third party patents; and
    • The impact of U.S. issues on European FTO analysis.

    FTO brochure In particular, C5 faculty will offer presentations on the following topics:

    • Developing and executing a successful and cost-effective FTO search strategy;
    • How to enforce or defend a patent claim in new markets;
    • EPO perspective on current FTO challenges;
    • Repositioning your FTO strategy to capitalize on the benefits of SPCs;
    • Utilising paediatric exclusivity to maximize the value of your portfolio;
    • Highlighting and contrasting the regulatory data protection application processes in Europe;
    • The impact of us developments on European FTO analysis;
    • Obtaining market authorisation to diversify your patent portfolio;
    • Insight into the emerging markets: A focus on China and India; and
    • Understanding the damages regime to categorise and respond to FTO risks.

    A post-conference workshop, entitled "Reading and Analysing Claims in Patents and Patent Applications: EU and US Jurisdiction-specific Issues" will be offered from 2:00 pm to 5:00 pm on May 19, 2011.

    The agenda for the Freedom to Operate conference can be found here.  A complete brochure for this conference, including an agenda, list of speakers, detailed descriptions of conference sessions, and registration form can be downloaded here.

    C5 The registration fee is €2394 for the conference and workshop and €1995 for the conference alone.  Those registering by April 15, 2011 will receive a €100 discount.  Those interested in registering for the conference can do so here, by calling +44 20 7878 6888, by faxing a registration form to +44 20 7878 6885, or by e-mailing registrations@C5-Online.com.

  • By Kevin E. Noonan —

    Federal Circuit Courtroom The Myriad case (AMP v. USPTO) came to the Federal Circuit on Monday for oral argument, and after months of briefing and public comment the parties did not deviate from their well-established positions (with the possible exception of Solicitor General Neal Katyal, whose argument for the government has become even more extreme than it was in the Department of Justice's amicus brief; see "DOJ Tries to Be All Things to All Constituencies in Myriad Amicus Brief").  But whatever information was to be gleaned from the proceedings came from the judges of the court, in a panel comprising Judges Lourie, Bryson, and Moore.

    A large portion of the arguments by Gregory A. Castanias of Jones Day, arguing for appellant Myriad, and Christopher A. Hansen of the ACLU, arguing for the plaintiffs, involved the important (and potentially dispositive) standing issue; those arguments will be the subject of a later post.  And except for a few short minutes, when the parties discussed the method claims at issue, the arguments were focused on the principal substantive issue in the case, whether isolated DNA is patent-eligible.

    Castanias, Gregory Mr. Castanias (at left) began his argument with the simple statement that "isolated DNA does not exist in nature."  Judge Bryson asked about the scope of the composition of matter claims by asking:  "I want to understand the scope of what you think your claim covers," specifically whether sequencing the "entire human genome" would infringe the composition of matter claims.  He stated that this is "an important question as to how preclusive your patent is," raising the possibility of having to license "hundreds" or "thousands" of patents to sequence the genome.

    While qualifying his answer by saying he was "not sure" Myriad had formed a view on that question, Mr. Castanias properly said that "whole genome" sequencing would not infringe, because the gene would not be isolated (with reference to the USPTO's utility guidelines).  He analogized Judge Bryson's hypothetical to the gene residing as it does in nature in the chromosome, and thus being outside the scope of the claim because it is not isolated.  Judge Bryson properly noted that "as long as you don't isolate that particular gene" and "do the test on something other than a gene-by-gene sequence" then a party would not infringe.

    Judge Bryson then asked about sequencing DNA comprising subject matter encompassed by claims 5 and 6 of the '282 patent, which are directed to the 15 nucleotide oligonucleotide fragments of the claimed BRCA genes:

    5.  An isolated DNA having at least 15 nucleotides of the DNA of claim 1.

    6.  An isolated DNA having at least 15 nucleotides of the DNA of claim 2.

    Mr. Castanias said sequencing such sequences would also not fall within the scope of these claims as they reside in the chromosome.  Judge Lourie asked about isolation methods that separated the coding portion of the genes from introns, which Mr. Castanias said would be covered if the DNA was "isolated."

    Mr. Castanias characterized the District Court's decision as reading into the law a "sweeping products of nature exception," which he said the judge attempted to limit to DNA but he predicted would have "consequences for all sorts of areas, including other areas of the biotechnology industry."  He admitted to the exceptions to patent eligibility contained in Chakrabarty regarding "a new mineral discovered in the earth or a new plant found in the wild," which provided Judge Moore with the occasion to ask him to distinguish isolating a mineral from a rock, requiring "extensive excavation" or "breaking the bonds" binding the mineral to the other materials in the rock, and asked "how is that really different from isolating DNA."  (One of the problems with many of these arguments, as with much of the debate, is that posing such questions disregards intrinsic scientific differences.)  Mr. Castanias responded by saying that "on some level," it is not different for § 101 purposes, because the isolated mineral should be eligible for a patent as a composition of matter.  He noted that there were other sections of the statute, particularly § 103, that could preclude patentability of the mineral.  Judge Moore followed up by noting that under § 103 the mineral would not be patentable if it were extracted using "routine methods," and that "routine methods" were used by geneticists to isolate the BRCA gene, and further that there was nothing "particularly unique" about BRCA1 compared to "the gene for pancreatic cancer or the gene for Alzheimer's or any of these other genes."  Mr. Castanias reminded the panel that there were important facts not considered by the District Court, including the state of the art in 1995 when the genes were isolated, that are part of the § 103 analysis but not part of a § 101 patent-eligibility analysis (which he called "a coarse filter").

    Persisting in following her hypothetical, Judge Moore asked Mr. Castanias whether the isolated mineral would be a patent-eligible composition of matter, and he replied that it should, "although it presents a close case."

    Judge Lourie pointed out that the mineral "is still the mineral" when in the rock, and it is physically but not chemically joined as a different molecular substance, whereas "[a] gene is distinctly different in the isolated state from what it is" in the body, which Judge Lourie says "reflects science in fact."  Mr. Castanias agreed, but when he mentioned the "complex efforts" it takes to isolate a gene, Judge Moore asked him to explain the relevance of the difficulty, and Judge Bryson noted that mining can be "difficult" and complex but that shouldn't change the patent-eligibility of diamonds produced by mining.  In response, Mr. Castanias tried to relate these efforts to the application of technology, but Judge Bryson asked if the argument was to distinguish between a mineral that was isolated by "breaking covalent bonds" from a mineral that was purified by, for example, "washing it with a solvent" to remove impurities.  Mr. Castanias replied that this is the kind of distinctions that are found in the case law, requiring the mineral to be "structurally or functionally different," and if it isn't then § 101 could be used to preclude patent-eligibility.

    When Mr. Castanias mentioned the Chakrabarty standard of an invention being the product of human ingenuity, Judge Moore asked why isn't it the process of isolating that is the product of human ingenuity, not the isolated DNA product "that was in your body, saying "God made it, man didn't make it."  Mr. Castanias responded with his best analogy, by noting that "only God can make a tree" and yet a baseball bat produced from wood can be patent-eligible, and that in a way that bat is "embedded" in the tree like DNA that is isolated is embedded in a chromosome.  Isolated DNA, he says, is not made by God but is the product of "molecular biology" and human ingenuity.

    He briefly turned to the method claims, saying that Judge Sweet made "a claim construction error" by considering the term "sequence" in the claims to mean the information represented by the letters of the gene's sequence.  Judge Lourie noted that the method claims recite broadly "analyzing, comparing, detecting," which he stated are "thought processes as opposed to concrete steps."  Mr. Castanias cited the Prometheus opinion (written by Judge Lourie) as the standard, that is transformative insofar as the claim recites a "determining" step (which Judge Lourie noted was not in these claims).  Mr. Castanias replied that a "determining" step was inherently in the claim, by virtue of there being a patient tumor sample and a germline sample ("these are things that are pulled out from a human body") from which the sequence must be determined.  He ended his argument by noting that the District Court had invalidated claim 20 of the '282 patent:

    20.  A method for screening potential cancer therapeutics which comprises:  growing a transformed eukaryotic host cell containing an altered BRCA1 gene causing cancer in the presence of a compound suspected of being a cancer therapeutic, growing said transformed eukaryotic host cell in the absence of said compound, determining the rate of growth of said host cell in the presence of said compound and the rate of growth of said host cell in the absence of said compound and comparing the growth rate of said host cells, wherein a slower rate of growth of said host cell in the presence of said compound is indicative of a cancer therapeutic.

    He characterized steps such as "growing" in this claim by saying that "if this isn't transformative, I don't know how anything could be."

    Hansen, Christopher Mr. Hansen's (at right) argument for the plaintiffs was that the identity of the sequence in the isolated gene and the gene in the chromosome meant that there was no difference between them (disregarding, as plaintiffs must, the physicochemical differences between isolated and chromosomal DNA).  He maintained that "Myriad's entire business is based on isolated DNA being identical to" chromosomal DNA.  In support of this assertion, he noted that Myriad analyzes BRCA DNA from a blood sample and when reporting the results does not say that they had "no idea" about the mutational status of the BRCA genes in the native state in the chromosome.  Of course, he neglected to mention that the isolated DNA claims would not be infringed merely by determining the sequence from a blood sample, provided the claimed BRCA DNA was not isolated.

    Judge Lourie addressed the "mere purification" argument from the District Court.  He noted the difference between purifying a chemical compound from a contaminant and isolating the gene from the chromosome, which involves breaking covalent bonds.  Mr. Hansen responded that "all" Myriad does is isolate the gene, "snip the gene out of the body."  In response to Judge Lourie's objection that "the gene isn't just sitting there" and that it "isn't easy," Mr. Hansen said that Myriad had not invented the methods for obtaining the BRCA gene and that the methods used were "well known in the science."  He said the claims were written so that if he could use a pair of tweezers to isolate the gene, then he would infringe.  He argued the isolated gene has "the exact same nucleotides" as in the native chromosome, but Judge Lourie interrupted by noting that Mr. Hansen's argument implied that the BRCA gene "was just sitting there" like "diamonds in a mine next to iron and uranium," which was not the case.  Mr. Hansen responded by using the metaphor of a kidney in "its natural state" in his body and that surgical removal of the kidney didn't make the kidney patentable (illustrating that bad analogies make bad law), saying that "the fact that the surgeon used a scalpel instead of a chemical is exactly irrelevant."

    Judge Bryson said he "was not sure about that," saying that "this gets to a really important issue in the case" for him.  Referring to Mr. Castanias' "bat in the tree" analogy ("but in a chemical setting"), Judge Bryson said that "there are many complex molecules that can be changed by lopping off some portion" thereof and "creating another molecule that was, in a sense, embedded in the first molecule" and that "all you have done is broken one or two covalent bonds," thereby "creat[ing] a molecule that does not exist in nature" that "may have functionality that is very different than the original."  In response, Mr. Hansen said the law requires that "the new thing we've created has different functions," "markedly different" in "character and kind."  He claimed that the isolated DNA is not different, and that "Myriad has offered no explanation and they can't," based on the argument about the identity of the sequence in the isolated DNA and the sequence in the chromosomal DNA (again, ignoring every other difference but the sequence).  Judge Bryson countered that the "functionality" difference is that the isolated DNA is "amenable to testing," because "you can't test the DNA  . . . in the original form in the body."  Mr. Hansen avoided addressing this argument directly, but made another (inapt) analogy, that "you can't use gold when it is in the mountain" to make jewelry and that a kidney is no less a kidney because you cannot use it for transplant when it is in the body.  Judge Lourie noted that "even if the functionality is the same" the isolated gene is different because "you've broken covalent bonds" in isolating it from the chromosome.  Mr. Hansen's response was that there is no difference between breaking covalent bonds versus "veins or arteries or rocks," saying that the relevant question is whether "the thing once I've taken it out is identical to the thing that was inside," again focusing on the sequence rather than the difference in chemical structure.  When Judge Lourie tried to distinguish Mr. Hansen's continued analogy that "half of gold is still gold" by saying "gold is gold," Mr. Hansen responded that "DNA is DNA," which pretty much sums up the level at which the ACLU wishes to keep the discussion.

    Judge Moore asked Mr. Hansen whether there was a difference between the "whole gene" and a fragment like cDNA or the oligonucleotide claims.  Mr. Hansen said that the specification "makes very clear" that the claims are not limited to cDNA.  He refuted patentability based on differences in functionality between the "whole gene" and the "primers and probes" by saying the use of the primers and probes is just the same as they are used in the body, meaning hybridization between complementary strands (again ignoring any of the many distinctions with how primers and probes are actually used).

    Turning to the method claims, Mr. Hansen maintained (after Judge Lourie asked him to address the Prometheus case) that the claims would be infringed if the publicly available BRCA sequence and a publicly available whole human genome sequence (using Professor George Church, who has published his entire genome sequence, as an example) were merely compared.  Turning to the Prometheus case, he said that the case involved "transformative activity" but that in plaintiffs' view "sequencing DNA does not involve any transformations" because "you don't have to isolate the DNA" in order to infringe.  In making this argument, Mr. Hansen of course inadvertently refuted his earlier arguments that the composition of matter claims were in any way relevant to the basis of the lawsuit, since the predicate for the suit was that these claims prevented the plaintiffs from practicing Myriad's claimed methods.

    Katyal, Neal Solicitor General Katyal (at left) presented the government's argument.  He began his argument by singling out claim 1 of the '282 patent:

    1.  An isolated DNA coding for a BRCA1 polypeptide, said polypeptide having the amino acid sequence set forth in SEQ ID NO:2.

    as being outside the scope of § 101 as interpreted by the Supreme Court.  Mr. Katyal brought to the court the rhetorical device of a "magic microscope," by which he argued that if the DNA as it resided in the chromosome was identical (presumably, in its sequence) as the isolated DNA, it was outside the scope of patent eligibility under § 101.  In response to Judge Moore's question regarding the oligonucleotide claims (e.g., claims 5 and 6 of the '282 patent), Mr. Katyal said that the fragment claims would also be "products of nature" if the "magic microscope" could detect those sequences in the chromosome.  This reading is contrary to the government's brief, where the synthetic nature of oligonucleotides presumably conferred patent eligibility.  cDNA, on the other hand, is patent eligible according to the government because it was not found in nature.

    Mr. Katyal characterized the government's position as being "a very limited position," "not a position that  . . . is going to dramatically undermine the biotechnology industry or destroy all the patents" raised in amicus briefs.  His position was clear and absolute:  if the product was found in nature, then it was not patent eligible, based on the government's reading of Supreme Court precedent.

    Judge Lourie took issue with the government's characterization of the claimed products in this case as "products of nature," on the grounds that the claimed genes were "bonded to other materials."  Mr. Katyal argued that the same could be said for minerals such as lithium, which "exist as salts with covalent bonds," but that "nobody would think that the third element in the periodic table" could be patentable because it doesn't exist in nature.  He argued that finding that an isolated gene was patent-eligible would be equivalent to finding that an "isolated electron" was patentable.  The extent to which the government is willing to maintain their position became clear when Mr. Katyal used the example of a discovery that pollen from a particular plant provided a cure for cancer, but that the purified pollen would not be patent eligible.  (Unmentioned was the more relevant hypothetical of a chemical compound isolated from that pollen.)  Mr. Katyal did agree with Judge Lourie that the legal basis for the District Court's opinion, that isolated DNA was the "physical embodiment of [genetic] information," was not correct and that the government did not support it.

    Mr. Katyal advanced the argument that there is "a cardinal distinction for 101 purposes between products of nature . . . and human-made invention, and the mere act of isolating a substance doesn't mean that it is a human made invention," based on the government's interpretation of Supreme Court precedent (which he seemed not to recognize is murky at best).

    In response to Judge Bryson's questioning about the differences between purifying (separating a molecule from impurities) and isolating (breaking bonds to convert one substance into another), Mr. Katyal cited breaking "covalent" bonds in purifying lithium or "breaking bonds" when uranium 238 is changed to uranium 235 in support of his patent-ineligibility argument (at which point Judge Lourie kindly suggested that the argument was entering into "facts (sic)" outside the record).

    Judge Moore raised "B12" and more importantly "antibodies" as examples of "products of nature" that would be patent-ineligible under the government's view.  Mr. Katyal maintained that the "earlier cases" all held that products of nature were "not patent-eligible" without acknowledging the effects the government's position can be expected to have.  He rebutted the examples in some of the briefs, notably taxol, because it was not patented (an outcome having to do not with patent ineligibility but with prior art issues which he failed to note).  He contended that process patents would be sufficient to "provide the correct incentives" for innovation (without citing any evidence for this proposition).  He also seemed to agree with the plaintiffs that claim 1 of the '282 patent and claim 1 of the '492 patent:

    1.  An isolated DNA molecule coding for a BRCA2 polypeptide, said DNA molecule comprising a nucleic acid sequence encoding the amino acid sequence set forth in SEQ ID NO:2.

    were patent-ineligible because the isolated DNA "has the same function as they did in the body" (basing patent eligibility on functional rather than a structural grounds).

    When Mr. Katyal stated that the government's interpretation of the law wasn't a dramatic change that "undoes things," Judge Moore vigorously disagreed.  She noted that the PTO has been granting isolated gene patents "for 35 years" so that the position Mr. Katyal was advocating was in fact a significant change.  Mr. Katyal argued that "the vast majority" of the isolated gene patents the PTO has granted are directed to "cDNA, recombinant DNA" and the like and thus were properly granted, but Judge Moore cited the PTO's Utility Guidelines as expressly reciting isolated genomic DNA as being patent-eligible subject matter.  Noting that those Guidelines have not been rescinded by the Office, she concluded that patent-eligibility for isolated genes appears to continue to be the PTO's view.  She noted that Mr. Katyal purported to be representing the government but that there seems to be a "split in the government" due to these inconsistencies.

    Mr. Katyal then revealed that the District Court decision in this case, as well as Judge Dyk's improvident concurrence in the Intervet case, prompted the government to conduct a "high level, comprehensive review" "for the first time" of patent eligibility of isolated DNA (which clearly expanded to all "products of nature").  He said that the U.S. government's opinion was that the PTO's grant of isolated DNA claims that encompassed genomic DNA was wrong:  "we couldn't write a brief that allowed the patentability of isolated DNA, for to do so would be to make lithium patentable, uranium, coal from the earth . . . and perhaps even base individual nucleotides . . . and we just couldn't do that."  He also characterized the PTO's input into this decision as not a thumb but an "elbow" on the scale.

    Judge Moore then raised the question of whether the Court should be the avenue for making this policy change, and that Congress should speak to this issue.  She said that she was "a little nervous" about expanding the number of exceptions to patent eligibility under § 101 "in light of 35 years of industry development" and "in light of a split in the executive" on this issue, asking "why isn't stare decisis a concern?"  Mr. Katyal said that the government had made a similar analysis and decided that this was "a pure question of law" and that "Congressional acquiescence alone" was not enough for the government to defer to Congress on this issue.  (Unspoken was the financial liability the government would face under the Takings Clause if Congress or the executive branch, rather than the courts, made such a sea change in the law after "35 years" of isolated DNA patents.)

    On rebuttal, Judge Moore carried out a line of questioning of Mr. Castanias regarding whether difficulty in isolating the gene should have any relevance to patent eligibility, but Mr. Castanias brought the argument back to the differences in utility based on citations to the record.  Rebutting the Solicitor General's arguments ('you don't have to engage in the line drawing the Solicitor General asks you to"), he cited the J.E.M. Ag. Supply v. Pioneer Hybrid case for the proposition that "Section 101 has been consistently understood by Congress and the  . . . relevant agency with expertise as encompassing isolated DNA," and that "the PTO and the entire biotech industry has been moored on the notion that isolation is enough to the human invention that's required."

    In response to Judge Bryson's question, Mr. Castanias argued that purified lithium should be patent eligible because it has "new utilities" not found in nature.  And he finished his rebuttal argument by emphasizing that the isolated DNA is not the entire sequenced genome," based on explicit citations in the patents-in-suit.

    As with most arguments, this one was replete with hypotheticals and questions from the bench intended to stretch the boundaries of the arguments to identify weaknesses and inconsistencies.  The arguments in general suffered from the tendency to argue from analogies that were tenuous to the subject matter at issue and in some instances completely inapt.  If the Federal Circuit reaches the substantive issues discussed herein, it is likely to be subject to en banc review, a petition for certiorari to the Supreme Court, or both.  The case is far from over.

    For information regarding this and other related topics, please see:

    • "Federal Circuit to Hear Argument in AMP v. USPTO," April 3, 2011
    • "Curiouser and Curiouser," February 16, 2011
    • "AMP v. USPTO — Briefing Update III," February 8, 2011
    • "Amicus Briefs in AMP v. USPTO: AARP," January 27, 2011
    • "AMP v. USPTO: Appellees' Brief," January 12, 2011
    • "AMP v. USPTO — Briefing Update II," December 16, 2010
    • "Amicus Briefs in AMP v. USPTO: Alynylam Pharmaceuticals, Inc.," December 15, 2010
    • "The Relevance of Patent Exhaustion in the Myriad Genetics Case," December 14, 2010
    • "AMP v. USPTO — Briefing Update," December 14, 2010
    • "Amicus Briefs in AMP v. USPTO: University of New Hampshire School of Law," December 12, 2010
    • "Amicus Briefs in AMP v. USPTO: Rosetta Genomics & George Mason University," December 8, 2010
    • "Academic Amici Refute ACLU Falsehoods in Gene Patenting Debate," December 7, 2010
    • "Amicus Briefs in AMP v. USPTO: Genetic Alliance," November 10, 2010
    • "BIO and AUTM File Joint Amicus Brief in AMP v. USPTO," November 9, 2010
    • "AIPLA Submits Amicus Brief in AMP v. USPTO," November 3, 2010
    • "IPO Files Amicus Brief in AMP v. USPTO," November 2, 2010
    • "AMP v. USPTO — Briefing Update," November 1, 2010
    • "DOJ Tries to Be All Things to All Constituencies in Myriad Amicus Brief," October 31, 2010
    • "Myriad Files Appeal Brief in AMP v. USPTO," October 28, 2010
    • "AMP v. USPTO — Briefing Schedule Update," August 22, 2010
    • "FCBA Submits Amicus Brief on Motion for Recusal in AMP v. USPTO," August 9, 2010
    • "Appellees Move for Recusal of Chief Judge Rader in AMP v. USPTO Appeal," July 19, 2010
    • "AMP v. USPTO after Bilski v. Kappos," July 6, 2010
    • "Myriad Appeals AMP v. USPTO Decision," June 16, 2010
    • "AMP v. USPTO: What Everyone Else Is Saying – Part II," June 8, 2010
    • "AMP v. USPTO: What Everyone Else Is Saying," April 6, 2010
    • "'60 Minutes' and 'Newshour' Take Different Approaches to Covering Gene Patenting Story," April 5, 2010
    • "'60 Minutes' Examines Gene Patenting Issue on Sunday, April 4th — Patent Docs Author Kevin Noonan to Appear on Program," April 2, 2010
    • "AMP v. USPTO: What the Parties Are Saying About the Decision," April 1, 2010
    • "Caught in a Time Warp: The (In)validity of BRCA1 Oligonucleotide Claims," March 30, 2010
    • "Round One Goes to the ACLU," March 29, 2010
    • "USPTO Asks out of Gene Patenting Case (Again)," January 19, 2010

  • By Donald Zuhn —

    USPTO Seal In a notice of proposed rulemaking published in today's Federal Register (76 Fed. Reg. 18990), the U.S. Patent and Trademark Office announced a proposal to revise the patent term adjustment (PTA) and patent term extension (PTE) provisions of the patent rules.  In particular, the Office is proposing changes to the PTA and PTE provisions with respect to some circumstances of appellate review and for the submission of certain information disclosure statements (IDSs).

    With regard to changes relating to decisions during appellate review, the Office notes that the PTA and PTE provisions provide for an adjustment or extension of patent term when the issuance of a patent is delayed by appellate review (by either a Federal court or the Board) reversing a prior adverse determination of patentability.  Under the proposed revisions, an examiner's reopening of prosecution following the filing of a notice of appeal would be considered, under most circumstances, to be equivalent for PTA or PTE purposes to a court or Board reversal of a prior adverse determination of patentability, and as such, patentees would be entitled to an adjustment or extension of patent term.

    The Office notes that under the current rules of practice, a decision by a pre-appeal brief conference panel to withdraw any or all of the claims on appeal is not a decision by the Board, and therefore would not result in any patent term adjustment or extension.  According to the notice, however, "[t]he Office has now concluded that it may and, in most situations, should treat a decision in a pre-appeal brief review reopening prosecution and issuing an Office action or notice of allowance as a 'decision in the review reversing an adverse determination of patentability' under 35 U.S.C. 154(b)(1)(C)(iii)."  The notice explains that "in many such situations the reopening of the application after notice of appeal has been filed is the result of a decision in the pre-BPAI review that there is some weakness in the adverse patentability determination from which the appeal was taken."

    The Office will not, however, treat any reopening of prosecution after the filing of a notice of appeal as a "decision in the review reversing an adverse determination of patentability."  The notice indicates that when an applicant files a request for continued examination (RCE) after filing a notice of appeal, the reopening of prosecution will not be considered to be a "decision in the review reversing an adverse determination of patentability."  In addition, any reopening of prosecution that results from an applicant's filing of an amendment cancelling all claims on appeal or a request to dismiss or withdraw an appeal will not be considered to be a "decision in the review reversing an adverse determination of patentability."

    With regard to the submission of certain IDSs, the Office proposes to change the rules of practice for PTA reductions due to applicant delay to exclude IDSs related to information cited by the USPTO in another application or by a foreign patent office in a counterpart foreign application.  In particular, the notice states that an applicant would no longer suffer a reduction in PTA when the applicant:

    [P]romptly submits a reference in an information disclosure statement after the mailing of a notice of allowance if the reference was cited by the Office in another application, or when applicant promptly submits a copy of an Office communication (e.g., an Office action) in an information disclosure statement after the mailing of a notice of allowance if the Office communication was issued by the Office in another application or by a foreign patent office in a counterpart foreign application.

    Pursuant to 37 C.F.R. § 1.704(d), prompt submission of information means that the information is submitted within 30 days of receipt.  The change with respect to IDS practice acknowledges recent decisions by the Federal Circuit in Dayco Products, Inc. v. Total Containment, Inc., 329 F.3d 1358 (Fed. Cir. 2003); McKesson Info. Solutions, Inc. v. Bridge Medical, Inc., 487 F.3d 897 (Fed. Cir. 2007); and Larson Mfg. Co. v. Aluminart Products Ltd., 559 F.3d 1317 (Fed. Cir. 2009).

    Written comments regarding the proposed changes must be submitted on or before May 6, 2011.  Comments should be sent by e-mail to AC56.comments@uspto.gov; by regular mail to:  Mail Stop Comments — Patents, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313–1450, marked to the attention of Kery A. Fries, Senior Legal Advisor, Office of Patent Legal Administration, Office of the Associate Commissioner for Patent Examination Policy; or via the Federal eRulemaking Portal at http://www.regulations.gov.  Additional information regarding the proposed rulemaking can be found in the Federal Register notice (76 Fed. Reg. 18990).

  • By James DeGiulio —

    Cephalon's Fentora Patent Found Valid, Infringed by Watson

    Cephalon #2 Cephalon enjoyed a needed victory in its patent dispute with Watson over Fentora after one of the patents at issue in the case was upheld and Watson's proposed generic of Fentora was found to infringe that patent.  The dispute between the parties began in June 2008, when Cephalon filed suit against Watson in the U.S. District Court for the District of Delaware over Watson's ANDA filing covering a generic version of Fentora (see "Court Report," June 8, 2008).  Cephalon alleged infringement of U.S. Patent Nos. 6,200,604 and 6,974,590.  In September 2009, Cephalon brought suit for infringement of U.S. Patent No. 6,264,981 (see "Court Report," October 4, 2009).  The cases were consolidated for purposes of discovery and a bench trial, which was held between May 10 and 17, 2010.  In early March, 2011 Judge Robinson found that Watson had established that the asserted claims of the '604 and '590 patents were invalid for lack of enablement (see "Biotech/Pharma Docket," March 15, 2011).

    Watson Pharmaceuticals In an opinion issued on March 24, Judge Sue L. Robinson effectively ended Watson's efforts to market a generic version of Fentora for the time being after determining that the proposed generic drug infringes four claims of the '981 patent.  Watson contended that its proposed fentanyl buccal tablets were not covered by the '981 patent because they contained an amorphous rather than a solid solution, but the District Court agreed with Cephalon's argument that fentanyl cannot be completely in amorphous form.  The Court also held that the proposed generic contained a buffer system and absorption mechanism protected by the '981 patent.  Judge Robinson subsequently denied Watson's motion to vacate a previously entered injunction preventing Watson from marketing its generic drug.


    Abbott Laboratories and WARF Settle Zemplar Patent Suit with Anchen Pharmaceuticals

    Abbott A Abbott Laboratories and the Wisconsin Alumni Research Foundation (WARF) entered into an agreement with Anchen Pharmaceuticals, thus ending a patent infringement dispute over a generic version of the kidney disease treatment Zemplar.  In October 2010, Abbott and WARF sued Anchen in the U.S. District Court for the District of Delaware, alleging that Anchen infringed U.S. Patent No. 5,587,497 when it filed an ANDA seeking approval to market generic Zemplar (see "Court Report," October 31, 2010).  WARF owns the '497 patent and exclusively licenses the patent to Abbott.  In their complaint, Abbott and WARF asked the court to prohibit the approval of Anchen's ANDA, enjoin the generics maker from marketing or selling paricalcitol capsules, and award the plaintiffs costs and attorneys' fees.

    Anchen Pharmaceuticals In January, the parties notified the District Court that Anchen was engaged in talks with the plaintiffs about the possibility of a settlement.  The Court agreed to grant Anchen a few months extra time to respond to the complaint, so the defendant could allocate resources to negotiating a settlement.  On March 23, Judge Gregory M. Sleet approved a joint stipulation filed by the parties, which agreed to dismiss all claims, counterclaims, and affirmative defenses in the suit without prejudice.  The parties also indicated that each would cover its own costs and attorneys' fees.


    Pronova Settles with Apotex in Lovaza Patent Dispute

    Pronovalogo Pronova and Apotex have reached an agreement settling their litigation over Lovaza, agreeing to allow Apotex to enter the market for the triglyceride-lowering drug beginning in 2015.  In April 2009, Pronova brought suit against Apotex in the U.S. District Court for the District of Delaware, alleging infringement of U.S. Patent Nos. 5,502,077 and 5,656,667 following Apotex's ANDA filing (see "Court Report," May 3, 2009).  Pronova filed an amended complaint adding infringement claims with respect to U.S. Patent Nos. 7,678,930 and 7,718,698.  In January, Pronova filed a new infringement suit in the District of Delaware over U.S. Patent No. 7,732,488 (see "Court Report," January 9, 2011).  These suits were combined with Pronova's similar suits against generic makers Teva Pharmaceuticals USA and Par Pharmaceutical.  The first trial against all three defendants with respect to the '077 and '667 patents was set for March 29.

    Apotex #1 On March 29, Pronova and Apotex agreed to voluntarily drop Pronova's two infringement suits that were scheduled to begin that same day, with each party bearing its own attorneys' fees and costs.  Judge Robinson signed off on the settlement that day, issuing a stipulated order, which did not contain details on market entry.  However, on March 30, Pronova and GlaxoSmithKline announced in separate press releases that the parties' settlement grants Apotex a license to enter the U.S. market with a generic version of Lovaza in the first quarter of 2015, or earlier depending on certain undisclosed circumstances.  The '077 patent expires in March 2013, while the '667 patent expires in April 2017.  Pronova's allegations against Teva and Par are still pending.